Septic bursitis, a potential complication of protease inhibitor use in hepatitis C virus

Clinical Infectious Diseases

Volumn 56, Issue 10, 2013, Pages 1507-1508

  Burke, Caitlin C ^a   Martel Laferriere, Valerie ^b   Dieterich, Douglas T ^b  

^a MOUNT SINAI HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BOCEPREVIR; CLINDAMYCIN; CLOBETASOL; DICLOXACILLIN; LEVOFLOXACIN; METHYLPREDNISOLONE; PEGINTERFERON; PREDNISONE; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; TRIAMCINOLONE;

ADULT; BACTERIAL GROWTH; BACTERIUM DETECTION; BURSITIS; CASE REPORT; CD4 LYMPHOCYTE COUNT; CELLULITIS; CORTICOSTEROID THERAPY; DRUG INDUCED DISEASE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECHOGRAPHY; EDEMA; ERYTHEMA MULTIFORME; HEPATITIS C; HUMAN; INCISION; JOINT EFFUSION; KNEE PAIN; KNEE RADIOGRAPHY; LETTER; LIVER CIRRHOSIS; MACULOPAPULAR RASH; MALE; PRIORITY JOURNAL; PUS; SEPTIC BURSITIS; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; WEIGHT BEARING; WOUND DRAINAGE;

BURSITIS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROTEASE INHIBITORS;

EID: 84877309342     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit090     Document Type: Letter

References (9)

1. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
2. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-24.
3. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
4. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
5. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705-16.
6. Hezode C, Dorival C, Zoulim F, et al. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 497 cirrhotic non responders.Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 9-13 November 2012. Abstract 51.
7. Muir AJ, Poordad FF, McHutchison JG, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with wellcharacterized prior treatment response. Hepatology 2011; 54:1538-46.
8. McAfee JH, Smith DL. Olecranon and prepatellar bursitis. Diagnosis and treatment. West J Med 1988; 149:607-10.
9. Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012; 55: 749-58.